ArticleJAAD case reports2019
Talimogene laherparepvec induces durable response of regionally advanced Merkel cell carcinoma in 4 consecutive patients.
Article in JAAD case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Updates on intratumoral therapies in melanoma.Cancer · 2026Review
- Treatment of Merkel cell carcinoma in organ transplant recipients-A systematic review.JAAD international · 2025Review
- A Novel Intersection: Cytomegalovirus Gastritis Following Cemiplimab and Talimogene Laherparepvec in a Patient With Advanced Cutaneous Squamous Cell Carcinoma.Clinical case reports · 2024Article
- Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates.American journal of clinical dermatology · 2024Review
- Therapeutic Approaches for Non-Melanoma Skin Cancer: Standard of Care and Emerging Modalities.International journal of molecular sciences · 2024Review
- The Evolving Treatment Landscape of Merkel Cell Carcinoma.Current treatment options in oncology · 2023Review
- Complete resolution of PD-1 refractory, locoregionally advanced Merkel cell carcinoma with talimogene laherparepvec.JAAD case reports · 2023Article
- Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy.Journal of clinical medicine · 2023Review
- A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors.Frontiers in pediatrics · 2023Article
- Review
- Talimogene laherparepvec resulting in near-complete response in a patient with treatment-refractory Merkel cell carcinoma.The Australasian journal of dermatology · 2022Article
- Scientific and clinical developments in Merkel cell carcinoma: A polyomavirus-driven, often-lethal skin cancer.Journal of dermatological science · 2022Review
- A systematic analysis on the clinical safety and efficacy of onco-virotherapy.Molecular therapy oncolytics · 2021Article
- Bespoke circulating tumor DNA as a biomarker for treatment response in a refractory Merkel cell carcinoma patient.JAAD case reports · 2021Article
- Talimogene Laherparepvec in Non-Melanoma Cancers.The Journal of clinical and aesthetic dermatology · 2021Review
- Multimodal Strategy in Localized Merkel Cell Carcinoma: Where Are We and Where Are We Heading?International journal of molecular sciences · 2021Review
- Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient.JAAD case reports · 2021Article
- Advances in Targeting Cutaneous Melanoma.Cancers · 2021Review
- How we treat Merkel cell carcinoma: within and beyond current guidelines.Future oncology (London, England) · 2021Article
- Current concepts and approaches to merkel cell carcinoma.Archives of dermatological research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.